New Clinical Study Results Demonstrate Rezūm is Proven to Give Men Suffering with BPH Sustained Symptom Relief and Quality of Life Improvements for 5 years

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Results of a five-year clinical trial confirming the long-term durability of Rezūm Water Vapor Therapy for treatment of benign prostatic hyperplasia (BPH) was published in the Journal of Urology. The supplement, available online now, includes standard and late-breaking abstracts for the American Urological Association (AUA) Annual Meeting.

The abstract notes that the study found the Rezūm System provided significant, sustained improvement of lower urinary tract symptoms (LUTS) and quality of life for patients suffering from BPH out to five years post-procedure. More detailed results will be released later this year.

Why:  BPH is a common condition that affects roughly half of all men by the age of 60, and up to 90 percent of men by the age of 85.(1) BPH can cause symptoms like frequent or urgent urination, a weak or interrupted urine stream, and the need to get up several times a night to urinate. Medications to treat BPH may not work for many or may have undesirable side effects.(2) And some minimally invasive procedures may only treat BPH symptoms, not the underlying condition.

At the end of the five-year trial, the medication and surgical retreatment rates were:

  • 4.4 percent of the Rezūm System patients required surgical retreatment through 5 years
  • 11.1 percent of the Rezūm System patients required medications through five years

The study also solidified the therapy’s International Prostate Symptom Score (IPSS), Qmax (peak urinary flow rate) and quality of life improvements at 48 percent, 49 percent and 49 percent respectively, all significantly improved from baseline.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.